ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing targeted RNA medicines for rare genetic neuromuscular disorders, announced today its participation in the following investor and industry events:
— 5th AnnualNeedham Private Biotech and MedTech CompanyVirtual 1×1 Forum
— October 14-15, 2025 (virtual)
— Frédéric Legros, Executive Chairman and CEO, will participate in one-on-one meetings with investors during the conference
— Chardan/Sanofi:The Double Helix Den: A closed-door symposium enabling unfiltered conversations on genetic medicines
— October 20, 2025, New York, NY
— Mr.Legros will be participating in a panel discussion titled “Clinical stage development:Balancing safety and maximizing clinical benefit”
— Chardan's 9th Annual Genetics Medicines Conference
— October 21, 2025, New York, NY
— Mr.Legros will participate in one-on-one meetings with investors during the conference
About ARTHEx Biotech
ARTHEx Biotech is a clinical-stage company developing targeted RNA medicines designed to precisely modulate gene expression. Its proprietary platform pairs selective oligonucleotides with tissue-specific delivery to reach skeletal muscle, heart, and brain. Its lead program, ATX-01, is in clinical evaluation for myotonic dystrophy type 1 (DM1), a rare neuromuscular disorder, in the Phase I/IIa ArthemiR™ trial. Building on this foundation, ARTHEx is advancing a pipeline of therapies for additional areas of high unmet need across muscular, CNS, and cardiac diseases.
The Company headquarters are in Valencia, Spain.
For more information on ArthemiR™, please visithttps://www.arthemir.comorhttps://clintrials.gov. For more information, please visitwww.arthexbiotech.comand engage with us onLinkedIn.
https://mma.prnewswire.com/media/2068054/ARTHEx_Biotech_Logo.jpg
https://edge.prnewswire.com/c/img/favicon.png?sn=LA94000&sd=2025-10-09
View original content to download multimedia:https://www.prnewswire.com/news-releases/arthex-biotech-to-participate-in-upcoming-investor-and-industry-events-302579236.html
SOURCE ARTHEx Biotech
https://rt.newswire.ca/rt.gif?NewsItemId=LA94000&Transmission_Id=202510090300PR_NEWS_USPR_____LA94000&DateId=20251009